By Helena Smolak
Sanofi backed its full-year guidance after higher first-quarter sales and profit that beat analysts' expectations.
The French pharmaceutical company said Thursday that business operating profit--one of its preferred metrics, which strips out exceptional items--rose 20% to 2.90 billion euros, equivalent to $3.28 billion, driven by a higher gross margin and slower operating expense growth.
Sales rose 11% to 9.895 billion euros on higher demand for its key drugs and vaccines and a favorable base of comparison.
Analysts expected business operating profit of 2.68 billion euros on sales of 9.64 billion euros, according to a poll of analysts by Visible Alpha.
Its business earnings per share were up 17% at 1.79 euros.
Sanofi stuck to its guidance for the year, expecting sales to grow by a mid-to-high single digit and business EPS at a low double-digit percentage, both at constant currencies.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
April 24, 2025 01:30 ET (05:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。